key: cord-0908851-brivvun5 authors: Kumar, Arun; Deka Dey, Asmita; Behl, Tapan; Chadha, Swati; Aggarwal, Vishal title: Exploring the Multifocal Therapeutic Approaches in COVID-19: A Ray of Hope date: 2020-11-03 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2020.107156 sha: e0250d6fdb60e9b5f03e3b6edc870089aeb633c5 doc_id: 908851 cord_uid: brivvun5 The ongoing global pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is marked as one of the most challenging infectious diseases in the history of mankind with affliction of ∼29,737,453 confirmed cases globally. Looking at the present scenario where there is a parallel increment in curve with time, there is an utmost emergency to discover a perennial solution to this life-threatening virus which has led the Human race in an unusual state of affair. The entire health care fraternity is engaged in endeavouring an ultimate way out to hit this pandemic but no such research made till now has been approved yet, to have the potential to bring an end to this fatal situation. Although a few possible treatment choices exist at the moment yet the requirement to search for a still better therapeutic option remains persistent. Global laboratories are working day and night in search for an effective vaccine, many are undergoing clinical trials but their commercialization is no less than a year away. The present review highlights the current potential therapies viz., vaccines, immunotherapies, convulsant plasma therapies, corticosteroids, antithrombotic, intravenous immunoglobulins, nocturnal oxygen therapy etc. that may prove beneficial in attenuating the pandemic situation. However, comparison and presentation of collective data on the therapeutic advancements in mitigating the pandemic situation needs further clinical investigations in order to prove boon to mankind. Over the span of last 6 months, the entire world has been put on halt by a new strain of corona virus which was not seen previously in human and was termed as "Novel Corona virus . The corona virus is an unsegmented, crown shaped, and positive-sense single stranded RNA virus belonging to the family Coronaviridae and sub-family Coronavirinae [1] . On the basis of distinct genetic attributes, the sub family of coronavirus is further classified into four genera namely: alpha, beta, gama, and delta coronaviruses. However, only alpha and beta genus are originated from bat and are responsible for the viral infection in human population. The virus SARS-COV-2 responsible for the current outbreak belongs to the beta genus [2] . A significant feature of the virus is its crown-like structure which comprises of the spike glycoprotein on its outer surface termed as spike protein or S protein which is further cleaved into two subunits S1 and S2 [3] . The virus binds to the host cell receptor at Receptor Binding Domain (RBD) which lies in S1 subunit, while the S2 subunit is involved in fusion of host and viral membranes, thereby leading to penetration of virus inside the host cell [4] . An idiosyncratic feature of SARS-COV-2 is the presence of furin cleavage site at the interface of S1 and S2 subunits which promotes the insertion of O-linked Glycans to T678, S673, and S686 [5] . By means of receptor mediated endocytosis, the virus makes its way into the host cell particularly via type-2-alveolar cells [6] . Due to the existence of polybasic furin cleavage site and O-linked glycans, mutation takes place on receptor binding site of S protein and thus promote the efficacious binding of SARS-COV-2 virus to the main receptor angiotensin converting enzyme 2 (ACE2) receptor [7] . Upon binding to the specific receptor, virus initially infects the lower airway and finally activates the immune cells to secrete inflammatory cytokines and chemokines into pulmonary vascular endothelial cells leading to Cytokine Release Syndrome (CRS) [8] . Interleukin-10 (IL-10), IL-7, IL-12, Monocyte Chemotactic Protein 1 (MCP1), Tumour Necrosis Factor-α (TNF-α) and Granulocyte Colony Stimulating Factor (GCSF) are the cytokines which are produced in larger quantity as when compared with other cytokines. Several studies have reported that high levels of IL-12, IL-7, IL-10, GCSF, MIP1α and TNF-α in blood has been found in some patients admitted in intensive care unit [9, 10] . The first COVID-19 case was stated in December 2019 from Wuhan, Hubei Province, China [11] . Initially five cases were reported (total of five cases and one death) with Acute Respiratory Distress Syndrome during the time span of December 18, 2019 to December 29, 2019 [12, 13] . Due to high degree of infectivity of SARS-COV-2, the world witnessed an unprecedented rise in the number of infected patients, starting from a handful of cases in China to catastrophically spreading across the boundaries infecting 216 countries worldwide. As per the weekly epidemiological update, presented by World Health Organisation (WHO), a total of 29,737,453 confirmed cases and 937,391 confirmed deaths have been reported till 17 September, 2020, with United States being the most affected country with a total of 6,530,324 established cases and 194,434 death cases followed by India with 5,118,523 cases and 83, 198 death cases [15] . Looking at the current scenario where there is a parallel increment in the curve with time, there is an utmost emergency to discover a perennial solution to this life-threatening virus which has led the human race in an unusual state of affair. The entire health care fraternity is engaged in endeavouring an ultimate way out to hit this pandemic, but no such research made till now has been approved yet to have the potential to bring an end to this situation. Meanwhile the drug discovery processes are going on in full swing, a number of antecedent antiviral drugs are sent for pre-clinical and clinical trials for SARS-COV-2 treatment. According to Coronavirus Treatment Acceleration Program (CTAP) Dashboard provided by The U.S. Food and Drug Administration (FDA), a total of 590+ drug development programs are in planning stage, 310+ reviewed trials, yet no treatment is approved by FDA. However, two drugs Remdesivir and hydroxychloroquine achieved authorization for emergency use [16, 17] . Remdesivir, an antiviral drug for Ebola virus has proven its ability in speeding up the recovery time in patients suffering from severe condition. However, this drug cannot be delivered in patients with severe hepatic disease and chronic renal impairment as it produces side effects like respiratory failure, hypertension, nausea, and elevation in the levels of liver enzyme [18, 19] . The results of randomized, open-label, phase III clinical trials conducted for the investigational drug, Remdesivir, by Gilead Sciences, reported that the intake of the drug successfully decreased the mortality rate of hospitalized patient [20] . Apart from this, Chinese Randomized Clinical Trial (RCT) supported study, carried out by Shenzhen in February 2020 suggested that the treatment with Favipiravir developed by Toyama Chemicals, could ameliorate the symptoms in initial and early stages. However, it failed to show similar outcome in cases with high severity [21] . Chloroquine, an anti-malarial drug also reflected as one of the promising drugs in in-line treatment, but its overdose was observed to be associated with acute toxicity. The hydroxyl derivative of chloroquine, hydroxychloroquine serves its immunomodulatory action and turned out to be a better option against SARS-COV-2 with respect to safety concerns. The drug not only demonstrated the potential of decreasing elevated levels of cytokines in the serum but also inhibited the phago-lysosome fusion by lowering the intracellular pH [22] . In a longitudinal study, carried out by Henry Ford Health System in Southern Michigan [23] a remarkable rise in the survival rate of hospitalized patients was observed upon administration of hydroxychloroquine alone as well as in combination with Azithromycin in the first 24 to 48 hours of exposure towards the virus. However, the use of hydroxychloroquine combined with Azithromycin was contradicted in many reports and hence it was interpreted to use this therapy only in patients under medical aid. Though many drugs tried to prove themselves to be efficient enough but Hydroxychloroquine and Remdesivir are implied potent drug candidate employed for treatment of viral infection [24] . Scientists have also demonstrated that influenza drug EIDD-2801, acting as a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, works on the principle of imitating nucleoside and this has successfully proven to be a better therapeutic and prophylactic agent against the devastating disease [25] . Unfortunately, all these treatment approaches are only contributing scanty towards the win and further examination of the medical therapies are still a necessity. On account of major health concern, present review article mainly focuses on presenting a collective data on the advancements towards curtailment of the pandemic so that worldwide researchers get an idea of the current status which will embolden them to meet current medical needs. Here we provide an insight into the mechanism and utility of newly emerging strategies viz., Vaccines, Immunotherapies, Convulsant Plasma Therapy, Corticosteroids, Antithrombotic Therapy, Intravenous immunoglobulins, Nocturnal Oxygen Therapy, Mesenchymal Stem Cell Therapy and Radiation Therapy along with the associated Clinical Trials and Patents filed worldwide. Advances in COVID-19 Therapies Innumerable bunch of repurposed and anti-viral drugs trial against SARS-COV-2 are predicted to help control the disease yet none is able to completely eliminate the virus from the biological environment. Under such circumstances, "Vaccination" proves to be a prime solution to control any infectious disease. Clinical researchers all over the world have raced for the development of an effective and efficient vaccine and so far, a total of 170 vaccine candidates are being monitored by WHO [26] . Several research scientists suggested that the Bacillus Calmette-Guerin (BCG) vaccination exploited against tuberculosis has shown to offer a protective effect against the viral strain. Aron et. al. [27] in an epidemiological study conducted lately, ascribed the nation-wise deviation in the SARS-COV-2 associated morbidity and fatality to the BCG reported to be capable of generating an anti-viral response in the animal model studies [37] . The ChAdOx1-nCOV19 is undergoing a randomized control Phase III clinical trial (NCT04536051) with 5000 volunteers with high risk of SARS-COV-2 exposure, enrolled in two cohorts. The study is estimated to be completed by September 2020 [38] . However, the safety of the vaccine remains a question among the health professionals as due to the occurrence of adverse effects in one of the participants the clinical trials for the vaccine was put on halt and are yet to be resumed in countries like US, India and South Africa [39] . Although the process of vaccine development is progressing in an accelerated fashion yet uncertainty prevails in the industrialisation of every new drug candidate registered for clinical trials and as per experts the estimated time is suggested to be 12-18 months [40] . However, in this regard the United States have taken a noteworthy step by initiating the Operation Warp However, in spite of the completion of phase III clinical trials the vaccine has gained approval but its safety and efficacy still remain uncertain and does have received a multitude of criticism from various organisation [44] . Owing to the perilous threat on the world health sector by the current SARS-COV-2 pandemic, repurposing of drugs and therapies has become a mandatory field of research. The novel coronavirus imposes a major menace on the human immune system. A beneficial therapy that might have the ability to reduce the action of the virus is Immunotherapy. Immunotherapy which is an exciting area of research for cancer treatment has changed the world's perspective towards cancer cure. The therapy was first discovered by the Father of Immunotherapy, William B. Coley, back in 1890s [46] . Immunotherapy is a form of biotherapy that fights against cancer by boosting the body's own immune system to recognize, target and remove cancer cells. Besides curing cancer, immunotherapy also holds a glorious history of healing viral infections including the members of coronavirus family comprising of SARS-CoV and MERS-CoV [47] . At the moment, among the various immunotherapy proposals, Monoclonal Antibody Therapy and Vaccination are the major area of concern for treatment against SARS-COV-2. On account of its safety profile, purity, receptor specificity and diminished risk of contamination by blood-borne pathogens, Monoclonal Antibodies are preferred passive immunotherapy for the infection. With 77.5% similarity in the spike glycoproteins, the attachment of the Receptor Binding Domain (RBD) present in the S1 subunit with the ACE-2 receptor in the host cell marks the onset of the infection in both SARS-CoV and SARS-COV-anti-coronavirus neutralizing antibodies [52, 53] . Although, the viral strains are structurally alike, the SARS-CoV specific, ACE-2 receptor targeted antibodies fails to combine with the receptors of SARS-COV-2 thereby generating an urge for further development in the therapy [54] . Monoclonal antibodies have the ability to recognise the epitopic region in S1 subunit and are aimed to cease the interaction between the RBD and ACE-2 receptor preventing the fusion of the membranes [55] . Three Human Monoclonal antibodies (HmAb) viz. B38, H4 and 47D11 showed promising outcome in neutralizing the SARS-COV-2 viral infection. 47D11 is the first SARS-COV-2 blocking HmAb designed by Wang and his co-workers [56] . activities. The antibodies were designed to block the binding between the RBD and ACE-2 receptor by forming their own complexes with the S1-RBD. A competition assay using Biolayer Interferometry (BLI) and a blocking assay using Fluorescence-Activated Cell Sorting (FACS) was performed to examine the ability to block the viral interactions, wherein the results demonstrated complete competition with ACE-2 receptor by B38 and H4, partial competition by B5 while no competition by H2 antibody. The study also proposed the fact that with partial overlapping, B38 and H4 were able to recognize the different epitopes on RBD. The authors assured that this evaluation further could be helpful in the development of smaller molecules or peptide drugs and inhibitors. Though Monoclonal Antibody therapy proves to be a promising candidate in neutralizing the viral strain, yet no antibodies have been marketed till now. Production of large-scale monoclonal antibodies is expensive, time consuming and intense thus limiting its utilization during the pandemic [58] . However, looking at the present condition with no effective therapeutic solution, the knowledge of neutralizing antibodies will provide the researchers a better outlook for vaccine development process. Hyperbolised immune response often known as Cytokine Storm Syndrome (CSS), contributed primarily by elevated serum levels of IL-6 is a hallmark of severely ill SARS-COV-2 patients with an increasing susceptibility to death. A fetching treatment strategy for quenching the inflammatory cascade is by inhibiting or modulating the IL-6 signalling pathway to mimic the SARS-COV-2 associated inflammatory response [59] . follow-up losses were reported. Alattar and his co-workers [63] presented the clinical records of 25 patients in which 36% of the cohort were successful in attaining primary outcomes, 52% were admitted still in ICU and 12% was the confirmed death rate. Capra et al. [ Although IL-6 inhibitors have presented promising outcomes in increasing the survival rate of hospital aided patients yet safety risk and substantial cost limits the widespread use of Tocilizumab in the fight against SARS-COV-2 pandemic [66] . Based on all the available evidences, immunotherapy can be stated as an upcoming defence against this viral disease. Several studies have reported that combination of immunotherapy with anti-viral drugs will produce excellent outcomes with former decreasing the viral load and reducing stimulus intended for inflammatory responses and the latter improving the dysregulated inflammatory response preventing lung injury. Convalescent plasma (CP) therapy has long been utilised effectively for treatment of multiple Given the scientific efficiency of CP, the FDA has approved clinical consent for employing CP for the treatment of critically ill SARS-COV-2 patients (FDA, 2020). On the grounds of the fact that corticosteroids are mainly responsible for the suppression of inflammation, a study was carried out in which a total of 41 patients were included, out of which 21% received corticosteroids. The initial idea of using steroids in treatment of acute respiratory distress was given by Stockman and his co-workers (through a meta-analysis; where he carried out the effect of steroids in patients of SARS-COV-1). The observations showed that corticosteroid therapy is associated with majority of side effects as it delays the viral clearance, can be responsible for diabetes, psychosis and avascular necrosis [91] . Table 3 . In a study conducted by Xiaofan Lu [93] , the role of corticosteroids (as adjuvant therapy) was The initial phase of SARS-COV-2 is marked with sustained high fever and cough for a time Numerous investigational agents are evaluated for its management and implication in SARS-COV-2 pandemic; mainly for the patients with severe disease. Table 4 The Figure 1 . Moreover, IgG dimers present in IVIG forms a barrier in activating FcγR on innate immune effector cells [105] . IVIG is a biological invention obtained from plasma of number of patrons and exploited for treatment of primary immunodeficiency, secondary immunodeficiency, and autoimmune disorders. IVIG offers passive immunization and fortification against comprehensive range of microbes, pathogens, and viruses. Hyperimmune globulin extracted from patrons with high antibody titters towards specific pathogens and is employed efficaciously in treatment of contagions, like cytomegalovirus and H1N1 influenza [104] . The access of SARS-COV-2 inside target cell is facilitated due to presence of transmembrane spike (S) protein which fixes it towards Angiotensin Converting Enzyme-2 (ACE-2) receptor. The S protein forms a homotrimer which bulges from pathogen surface. The binding with receptor site is initiated by S1 subunit with aid of RBD that further results in the S2 subunit activation and imparts the blending amongst the viral and the cell membrane [105] . As per it induces the process of glycolysis, which offers broad supply of carbon for production of amino acids along with nucleotides essential for virus replication [111] [112] [113] [114] . Several studies have reported that vaccinia virus, hepatitis B virus, H1N1 virus can stabilize hypoxia inducible factor 1α (HIF-1α) by its degradation at normal oxygen conditions [115] . It is a widely known fact that HIF-1α induces metabolic transformation to glycolysis from biogenesis. In fact, studies also disclose that human B19 erythrovirus gene expression and multiplication of hepatitis C virus can be boosted by hypoxia. The above results clearly demonstrate that HIF-1α plays an important part in enhancing viral replication. However, the activity of HIF-1α gets reduced via hydroxylating two proline residues within HIF-1α under normoxic conditions [116] [117] [118] . No data or evidence is there which proves that supplemented oxygen is responsible for minimizing HIF-1α expression in the cells affected by the virus, scholars have documented a substantial decrease in HIF-1α expression in the kidney subjected to in-vivo hyperoxic conditions [119] . As a result, hypothesis states that primary effective oxygen therapy for SARS-COV-2 patients is anticipated to obstruct the coronavirus-2 replication process by downregulating HIF-1α expression. Median duration of SARS-COV-2 patients from first sign to dyspnoea was 5 days [120] , approximately associated with a cytokine storm and lead to injury or failure of many organs. Till now, the mechanism has not been fully explored but it is predicted that early vigorous replication of the virus possibly interrupts the immune response and promote the consequent inflammation. Type 1 interferon is a prime constituent of our innate immunity. It can activate transcription factors and promote host cells to confront the viral contamination. But unfortunately, SARS-CoV, having similarity with SARS-COV-2 is verified to impede production of IFN-1 in animal models [121] . Therefore, it is of foremost importance towards grasping mechanism of action of the virus replication to resolve the response of interferon so as to take effective measures. Investigators have recently indicated the accumulation of lactate due to glycolysis or via enhanced levels of Lactate Dehydrogenase (LDH) enzyme may act as promising mechanism for virus to down-regulate the assembly of interferon [122] . It is noteworthy that clinical studies have displayed that high levels of LDH or lactate have been found in a few patients infected with the virus, specifically the ones with poor prognosis [123] . As per the clinical data from SARS-COV-2 infected patients in Wuhan, China, LDH increased by 29/40 (73%), ICU care12/13 (92%) and ICU care 17/27 (63%) [124] . Therefore, inhibition of glycolysis and lactate reduction production is expected to initiate the antiviral immunity in the first phase of viral infection. As described above, oxygen may influence the functioning of Not long ago, medical scientists found that peripheral blood lymphocyte subset in SARS-COV-2 patients also found that the depletion in CD8 + T, CD4 + T, and NK cells was 68.3%, 60.16%, and 36.59% correspondingly, which tremendously weakens the immune system [125] . In order to deal with early SARS-COV-2, till date, no distinct master plan has been recommended to meliorate the body's immune system. Around the same period, the preventive influence of oxygen treatment in extreme conditions has contributed to the effects of oxygen on the immune system. It is also tempting to believe that ample oxygen will boost the antiviral potential in patients with early SARS-COV-2 infection by amplifying the abundance and functionality of immune cells. Studies on SARS-CoV may also help to explain SARS-COV-2. Analysis also shows that SARS-CoV genome was located in heart of 35% (7 of 20) of patients, suggesting heart attack was related with previous deaths [126] . Studies on renal functions of patients with SARS-COV-2 virus also explored that acute renal damage fostered by SARS-CoV was associated with peaked mortality rates [127] . Additionally, the collected clinical data suggest that rate of renal damage is unarguably greater in patients with SARS-COV-2 as compared with SARS-CoV [128] . Such several lines of proof suggest that SARS-COV-2 is capable of infecting the heart and lungs with ACE-2 and can inflict significant harm in patients. Minimizing the manifestation of ACE-2 in organs at the initial phase of infection with SARS-COV-2 is therefore required for prevention of virus invasion. Studies have shown that ACE-2 transcription is enhanced due to hypoxia, by up-regulating SIRT1 expression on Huh cells which increases ACE-2 expression in a HIF-1α dependent manner on CD 34 + cells [129, 130] . Hypoxia was also shown to increase expression of ACE-2 inside pulmonary vascular smooth muscle cells. Therefore, administration of hypoxia is also likely to postpone the development of SARS-COV-2 in the early stages. Oxygen abundance can elevate the partial pressure of O 2 in arterial blood by increasing O 2 pressure and boost tissue oxygenation which is known to boost myocardial ischemic functioning [131, 132] . Thus, early effective oxygen treatment in SARS-COV-2 patients can counteract the rapid annexation of virus. As the cytokine storm is presently esteemed to be a major reason of the most important SARS-COV-2 explosion, initial steps must be occupied to prevent or minimize unrestricted secretion of inflammatory cytokine. Production of cytokines in the sapiens blood indicates the diurnal rhythmicity. Pro-inflammatory cytokines production (mainly TNF-a, IL-1, IFN-γ, and IL-12) occurs higher at night and in the early morning when plasma cortisol is very low [133] . A successive research during a human in-vivo trial has shown that whole blood stimulation demonstrated elevated cytokine and chemokine levels at night and early in the morning in a healthy volunteer [134] . Consequently, the elimination of nocturnal pathogen, replication is anticipated to disrupt the synthesis of inflammatory factors. Whether viral proliferation is associated with time-of-day, particularly once virus infects host cell, additional investigation is still required here [135, 136] . In accordance with the mentioned studies, it can be hypothesized that nocturnal oxygen therapy could prolong the progression of SARS-COV-2 disease. Since it is not a new concept, it is safe, reliable and user friendly in clinical practice. With the growing demand for the key to this unsolved mystery of SARS-COV-2 pandemic, innumerable researches, clinical trials are conducted in the laboratories worldwide, countless literatures are being published yet neither any pharmacological approach nor any therapy-based treatment procedure has been able to address the crisis. In recent times, stem cell therapy has established itself as one of the most effective and promising treatment strategies for diseases that were earlier esteemed to be incurable [137] . One such emerging therapy expected to show results is Mesenchymal Stem cell Therapy. Mesenchymal stromal cells (MSC's) have potential utility in a range of cellular therapies with application related to tissue engineering, immunomodulation and vehicle for gene therapy. Based on the capability of stem cell to show resistance to tissue damage, immunomodulatory effect along with promoting tissue repair, dedicated researchers worldwide have begun to consider its benefits in the treatment of SARS-COV-2 pneumonia [138] . The robust anti-inflammatory activity produced by the mesenchymal stem cells, forms the basis for the mechanism of action in treating SARS-COV-2 patients [139] . Immunomodulatory activity and proliferation ability of MSC paves the way for SARS-COV-2 treatment [140] . Radiotherapy, as a cancer treatment has been in use for over a century. The therapy has successfully presented outstanding outcomes in healing the silent killer disease. Radiotherapy is a treatment procedure based on the application of radioactive agents or ionising radiation energies to destroy the cancer cells and to put an end to the growth and proliferation of tumoral cells [150] . In view of the current deadly pandemic, Radiotherapy has also been sought as a therapeutic tool to halt the complications associated with the disease. Upon the exposure to the coronavirus, two distinct yet overlapping pathological subsets seems to appear, initially triggered by the virus itself followed by the host response. During the second stage, patients generally establish lung disorders developing viral pneumonia accompanied by hypoxia, cough and fever. The Chest Radiograph images or the Computed Tomography displays ground glass opacities with bilateral infiltrates. The necessity of medical aid in majority of SARS-COV-2 patients arise at this stage [151] . Pneumonia tends to be a severe complication that follows the onset of the infection followed by Cytokine Storm Syndrome, with minority of patients leading to Acute Respiratory Distress Syndrome (ARDS) resulting in death owing to respiratory failure [152] . Pneumonia has long been a serious threat to the global health. Prior to 1939, Serum Therapy was the principal cure for pneumonia. However, in 1930s radiotherapy came into light as a potential therapeutic option for the illness. Calabrese and co-workers [153] demonstrated the utilisation of Low Dose Radiotherapy (LD-RT) to treat pneumonia back in 20th century. The authors reviewed and presented a report of 15 studies on around 700 patients suffering from bacterial, interstitial, atypical and sulphanilamide-resistant pneumonia treated with LD-RT. They reported that an average of 30% to 10% decrease in the pneumonia mortality rate was observed when low dose radiation therapy was provided. By the beginning of the second decade of the 20th century, radiotherapy was widely accepted by the radiological community with significant achievement in healing severe diseases like carbuncles [154] , sinusitis [155] , arthritis [156] , etc. SARS-COV-2 pneumonia poses a major threat on the survival rate of the affected patients especially for the ones falling in the high-risk categories (geriatric patients, hypertension, cardiovascular complications, diabetes and elevated levels of inflammatory Dimer D/ Ferritin) [157] . Cytokine storm plays a significant role in the critical cases of SARS-COV-2 pneumonia. Suppressing the cytokine storm by inhibiting or neutralising IL-6 and IL-1 is a key factor for reducing the lethality of the infection [158] . On the basis of several clinical accomplishments in the past, and given current insufficiencies in treatment for the disease, scientific scholars have undoubtedly initiated an exploratory attempt of assigning LD-RT to treat SARS-COV-2 pneumonia. Low Dose Radiotherapy (0.5 Gy) is a non-toxic, cost effective, evidence based anti-inflammatory therapeutic tool that could improve the respiratory complications and normalise the immunity cascade in the patients suffering from SARS-CVO-2 pneumonia. The therapy emerges as a better alternative for patients who are sensitive to common anti-inflammatory treatments [159] . Usually doses greater 200 cGy exerts proinflammatory response however, recent studies have evinced that low doses less than 100 cGy are able to provoke anti-inflammatory effects [160, 161] . Calabrese et al. [162] proposed that LD-RT induces polarization of macrophages into a M-2 anti-inflammatory phenotype. As shown in Figure 4 , the anti-inflammatory phenotype initiates the obstruction of leukocyteendothelial cell interaction, reduces the endothelial adhesion molecule production, lowers the inflammatory mediators and also decreases the expression of pro-inflammatory cytokines [152] . Moreover, by inducing polynuclear apoptosis, secreting anti-inflammatory cytokine TGF-β1, reducing the applications of macrophages and through several other mechanisms, LD-RT potentially reduces the elevated levels of Nitric Oxide (NO), decreases the inducible nitric oxide synthetase (iNOS), L and E selectins, lowers the Tumour Growth Factor-alpha (TGFα), TNF-α or IL-β1 secretions, and decreases the levels of Reactive Oxygen Species (ROS) [163, 164] . Based on all of these changes, LD-RT treatment (30-100 cGy) to the lungs of SARS-COV 2 patients could taper off the pneumonia associated inflammation by creating an antiinflammatory environment and also lessen the probability of death [165] . implemented if approved as a cure for SARS-COV-2 pandemic [164] . Hopefully, the researchers will find an answer to this pandemic, overcoming all the limitations in the medical treatments evaluated so far, retrieving the global health system and gaining normalcy in the entire globe. In the era of SARS-COV-2, the livelihoods of people are at a stake. No matter various therapies are assigned to combat this devastating situation yet more and more findings are required to meet the global demand. With numerous publications, research ideas and pre-existing drugs the clinical representatives have so far managed to reduce the intensity of the situation. At present there are more than 100s of pharmacological drugs and therapy-based treatments undergoing clinical trials. Hopefully, the world will soon be gifted with a solution to terminate this novel coronavirus 2019 disease and a chance to restore the global health. Emerging coronaviruses: Genome Structure, replication and pathogenesis Advances in the possible treatment of COVID-19: A review The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex Structure, Function, and Evolution of Coronavirus Spike Proteins Coronavirus Disease An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics The Proximal origin of SARS-CoV-2 Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Elevated plasma level of selective cytokines in COVID-19 patients reflect viral load and lung injury The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Novel SARS-CoV-2 outbreak and COVID19 disease; a systemic review on the global pandemic A review of coronavirus disease-2019 (COVID-19), Ind Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study Weekly Epidemiological Update-14 The critical role of futility analysis in the pursuit of effective treatments for COVID-19 COVID-19 Treatment: Close to a Cure? -A Rapid Review of Pharmacotherapies for the Novel Coronavirus A Randomized Controlled Trial of Ebola Virus Disease Therapeutics A review of the safety of Favipiravir -a potential treatment in the COVID-19 pandemic? Virology, pathogenesis, diagnosis and in-line treatment of COVID-19 COVID-19 Task Force Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak Biological products: cellular therapy and FDA approved products Draft Landscape of COVID-19 Candidate Vaccine-9 Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study, medRxiv Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19 Impact of routine infant BCG vaccination in young generation on prevention of local COVID-19 spread in Japan Bacillus Calmette-Guerin (BCG) vaccination and COVID-19: Scientific Brief. Available at: www.who Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study World Health Organization. Draft landscape of COVID-19 candidate vaccines -15 Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults A study to evaluate the efficacy, safety and immunogenicity of MRNA-1273 vaccine in Adults aged 18 years and older to prevent COVID-19 Operation Warp Speed on Track for End of Year Vaccine Delivery ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaque A Study of a Candidate COVID-19 Vaccine (COV003), Sponsored by Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins Discovery of SARS-COV-2 antiviral drugs through large-scale compound repurposing Coronavirus: Operation Wrap Speed Developing Safe and Effective Covid Vaccines-Operation Wrap Speed's Strategy and Approach, The New Eng Fact Sheet: Explaining Operation Warp Speed The Russian vaccine for COVID-19 A Brief History of Immunotherapy, targeted oncology The possible of immunotherapy for COVID-19: A systematic review Coronaviruses-drug discovery and therapeutic options Monoclonal antibody as a potential anti-COVID-19 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Structural, function and antigenicity of the SAS-CoV-2 spike glycoprotein Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus A human monoclonal antibody blocking SARS-CoV-2 infection A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Therapeutic antibodies for infectious diseases SITC Statement on anti-IL-6/IL-6R for COVID-19-Society for Immunotherapy of Cancer (SITC National Health Commission and National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7) Effective treatment of severe COVID-19 patients with tocilizumab Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study Tocilizumab for the Treatment of Severe COVID-19 Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response cytokine storm and immunomodulatory therapy in COVID-19: Role of Chloroquine and anti-IL-6 monoclonal antibodies Treatment of severe acute respiratory syndrome with convalescent plasma Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systemic Review and Explanatory Meta-Analysis A potentially effective treatment for COVID-19: A systemic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease Convalescent Plasma to Treat COVID-19 Possibilities and Challenge Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study Treatment of 5 critically ill patients with COVID-19 with convalescent plasma The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study, medRxiv Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment with convalescent plasma for COVID-19 patients in Wuhan Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection Treatment of severe acute respiratory syndrome with convalescent plasma Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital Use of convalescent plasma therapy in SARS patients in Hong Kong Advances in clinical diagnosis and treatment of severe acute respiratory syndrome Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area Letter to editor Treatment of severe acute respiratory syndrome with convalescent plasma Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience, Anti-vir Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome Current status of potential therapeutic candidates for the COVID-19 crisis Adjuvant corticosteroid therapy for critically ill patients with COVID-19 The epidemiology, diagnosis and treatment of COVID-19 Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial Ongoing clinical trials for the management of the COVID-19 pandemic COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Personalizing Antithrombotic Therapy in COVID-19: Role of Thrombo-elastography and Thromboelastometry Thrombo-inflammation and the hypercoagulability of COVID-19 Ten Cate, B. Spaetgens, Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID-19 Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge The versatile heparin in COVID-19 Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Antibody responses to SARS-CoV-2 in patients with COVID-19 A possible role for B cells in COVID-19?: Lesson from patients with High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication ChREBP, a glucose-responsive transcriptional factor, enhances glucose metabolism to support biosynthesis in human cytomegalovirus-infected cells A role for vaccinia virus protein C16 in reprogramming cellular energy metabolism Kaposi's Sarcoma Herpesvirus MicroRNAs Induce Metabolic Transformation of Infected Cells Influenza A virus (H1N1) triggers a hypoxic response by stabilizing hypoxia-inducible factor-1alpha via inhibition of proteasome Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells Low Oxygen Tension Enhances Hepatitis C Virus Replication The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses Hyperoxia exposure impairs nephrogenesis in the neonatal rat: role of HIF-1α Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study Clinical features of patients infected with 2019 novel coronavirus in Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study Caution on Kidney Dysfunctions of 2019-nCoV Patients Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress COVID-19 with silent hypoxemia, Tidsskrift for Den norske legeforening Oxygen therapy and toxicity. The Veterinary clinics of North America Effect of 100% oxygen administration on infarct size and left ventricular function in a canine model of myocardial infarction and reperfusion The chronobiology of human cytokine production Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications Role of cell culture for virus detection in the age of technology SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract Biological products: cellular therapy and FDA approved products Current status of cell-based therapies for respiratory virus infections, applicability to COVID-19 Mesenchymal stem cells as a potential therapy for COVID-19 Mesenchymal stem cells (MSCs) as novel therapeutic option for nCOVID-19-A review Prevention of LPS induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1 Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury COVID-19: the vasculature unleashed Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells-A case report Transplantation of ACE2-mesenchymal stem cells improve the outcome of patients with COVID-19 pneumonia Mesenchymal stem cell therapy in severe COVID 19: A retrospective study of short-term treatment efficacy and side effects The rationale of using mesenchymal stem cells in patients with COVID-19 related acute respiratory distress syndrome: What to expect Radiotherapy overview presented by www.nhs.uk COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial How Radiotherapy was historically used to treat Pneumonia: Could it be useful today? X-ray treatment of carbuncles and furuncles (boils): A historical assessment The historical use of radiotherapy in the treatment of sinus infections Reduction of arthritic symptoms by low dose radiation therapy (LD-RT) is associated with an anti-inflammatory phenotype Clinical features of patients infected with 2019 novel coronavirus in Wuhan COVID-19: consider cytokine storm syndromes and immunosuppression Low dose lung radiotherapy for COVID 19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy Low-dose radiation therapy for benign pathologies Radiotherapy treatment of human inflammatory diseases and conditions: optimal dose Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved Low dose radiation therapy as a potential lifesaving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS), Radio-ther Is low dose radiation therapy a potential treatment for COVID-19 pneumonia? Radiotherapy for COVID-19: Primum non nocere, Radio-ther The authors would like to express gratitude to Chitkara College of Pharmacy, Chitkara University, Punjab, India for providing elementary facilities required for completion of article. Authors declare no conflict of interest. Authors did not receive any funding for this study.